Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.
about
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin DrugsEvaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countriesProtective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infectionRabies in the 21 centuryEngineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.Feasibility of sustainable provision of intradermal post exposure prophylaxis against rabies at primary care level--evidence from rural HaryanaRenewed global partnerships and redesigned roadmaps for rabies prevention and controlQuantifying antigenic relationships among the lyssaviruses.Molecular Pharming: future targets and aspirations.Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3.Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Evaluation of rabies biologics against Irkut virus isolated in China.Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of In vitro and In vivo studies.Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies.Rabies vaccines: where do we stand, where are we heading?Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device.Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.Rabies vaccination at a virus-inoculated site as an alternative option to rabies immunoglobulin.Development of monoclonal antibodies suitable for rabies virus antibody and antigen detection.Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus.Versatile and on-demand biologics co-production in yeast.SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.Recombinant monoclonal antibody yield in transgenic tobacco plants is affected by the wounding response via an ethylene dependent mechanism.Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its CureIn Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants
P2860
Q26863621-923ADFFB-60DC-4491-A6B5-08B9077FEA0CQ27306442-D4DE41C6-824C-484E-A80F-AE8B3E8A51CFQ27324824-A3EF2CCD-C2FF-4135-B5D3-D1F747E50BE3Q33548766-BFDFA2E5-0904-49AC-AF0E-46294364AE5BQ33816066-405675BB-3337-439F-88F2-04D5371EBA97Q33826458-0188F532-EF21-438E-A47B-5113A81B6DA4Q34202345-8B444C5A-3F6B-4718-825B-90DEAEE36A88Q34296085-21484E72-6EA7-47FC-BB38-B634E0D94C75Q35592164-94F577F5-5CF6-4537-810A-CF1B96EEF0C9Q36079932-5EF566EC-3DD8-43E2-BAE7-31CA7E59B182Q36788708-9529885E-4CA7-44D0-83F5-6C81DEC71810Q36911369-72A0608A-66B9-4F39-A249-BED7DC34A16DQ37470270-9D273965-F1BF-4DBA-A369-E11F625639E5Q37530343-519BB316-D5DB-4900-97E7-75DDC336C20BQ37664750-084F2FAC-9498-44B0-8446-6BE9FA53A75FQ38263028-B7B7E224-1AB1-4DD7-A6D7-959291965C25Q38545125-06DC49E0-0178-48EF-B1F4-B60D520BB97DQ38713139-77552D2F-F2D7-40C2-9778-157D2402A091Q40355293-E2A459FD-35D4-4E99-B1EA-9DC2D86389C5Q40715034-BE95E673-2E97-407C-9D03-702B260A5DA3Q41825900-E0171564-1358-4BC6-9A39-34FD5FEA091EQ42680315-3CD0CCBF-07D3-425A-B6C2-443F167BEB13Q47192978-EAA101CF-5EAB-4B8F-B46C-81D219B7F901Q47562878-6CD9F991-94D9-458E-B1C2-D1336FE7D36AQ51813053-67964BE9-E5D2-4496-966A-640DF13816A8Q56741242-965784DB-52FB-43C4-85C4-82A6F8ECD7F7Q56996860-E3C29FD3-F2F8-4414-B4B5-B94E07B49593
P2860
Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@ast
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@en
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@nl
type
label
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@ast
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@en
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@nl
prefLabel
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@ast
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@en
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@nl
P2093
P2860
P50
P1476
Development of a mouse monoclo ...... rabies prophylaxis in humans.
@en
P2093
Alexander I Wanderler
Anthony R Fooks
Bernhard Dietzschold
Christine Fehlner-Gardiner
Francois X Meslin
Hildegund Ertl
Jeannette Kliemt
Noël Tordo
Richard Franka
Thomas Müller
P2860
P356
10.1371/JOURNAL.PNTD.0000542
P407
P577
2009-11-03T00:00:00Z